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cell context of molecular alterations 
that play a role in brain tumors and 
do provide important further insight 
into the role of Bmi1 in brain tumori-
genesis. The finding that distinct 
tumor phenotypes that arise from 
transformation of different cell 
populations in the brain suggests 
that knowing the cell of origin may 
be important for understanding the 
prognosis of the tumor. It will likely 
also be important to determine the 
signaling mechanisms that subse-
quently become operational in the 
different cell contexts to devise new 
therapies.
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Trastuzumab is an established therapy for women with breast cancers that overexpress HER2. 
Despite its proven benefit in treating breast cancer, not all women derive benefit from this mono-
clonal antibody, and resistant disease can develop. In this issue of Cancer Cell, Berns et al. present 
evidence that activation of the PI3 kinase pathway, either via loss of the tumor suppressor PTEN or 
through oncogenic stimulation of PIK3CA, can mediate trastuzumab resistance. This study extends 
important work of others and forms the rationale for future investigations combining inhibitors of the 
PI3 kinase pathway in conjunction with trastuzumab therapy.One of the most successful examples 
of targeted therapies for epithelial 
cancers has been the demonstration 
that breast cancers with amplifica-
tion of the ERBB2/HER2 oncogene 
are responsive to trastuzumab (Her-
ceptin), a humanized monoclonal 
antibody directed against the trans-
membrane HER2 protein. As a result, 
patients whose breast cancer cells 
demonstrate overexpression of HER2 
protein by immunohistochemistry 
and/or gene amplification by fluores-
cence in situ hybridization (FISH) are candidates for this therapy in both 
the adjuvant and metastatic settings 
(reviewed in Hudis, 2007). However, 
as with many cancer therapies, not 
all women whose tumors overex-
press HER2 will respond to trastu-
zumab. Indeed, only about one-third 
of women with newly diagnosed 
advanced breast cancer that over-
expresses HER2 demonstrate tumor 
regression with trastuzumab mono-
therapy (Vogel et al., 2002). Also, 
trastuzumab treatment is not without 
cost in both economic and human Cancer Cell 12terms. Although it is generally well 
tolerated, rare but significant car-
diac toxicity can develop in patients 
receiving this therapy, especially 
when it is given in close proximity 
to anthracycline chemotherapy. One 
year of trastuzumab therapy, the cur-
rent standard regimen in early breast 
cancer, costs approximately $50,000 
(USD). Therefore, the identification of 
predictive biomarkers that can more 
accurately select responders or non-
responders is vital to improve the 
therapeutic index of this agent. Also, , October 2007 ©2007 Elsevier Inc. 297
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genetic pathways involved 
with trastuzumab resistance 
might allow rational design 
of combination therapies 
to overcome the resistance 
phenotype.
The study by Berns et al. 
in this issue of Cancer Cell 
is an additional step in this 
direction (Berns et al., 2007). 
Using an unbiased RNA 
interference (RNAi) genetic 
screen, these investigators 
identified the PTEN gene as 
a mediator of trastuzumab 
resistance in the HER2-over-
expressing breast cancer 
cell line BT474. Reduced or 
absent expression of PTEN, 
a known tumor suppressor, 
is seen in a significant frac-
tion of human breast malig-
nancies. Because PTEN is 
a negative regulator of the 
PI3 kinase pathway (Figure 
1), one might suspect that 
activation of this pathway 
via other means could also 
lead to a similar trastu-
zumab-resistant phenotype. 
Recently, several groups 
have demonstrated that 
hot spot missense muta-
tions in the gene encoding 
the p110α catalytic subunit 
of PI3 kinase, PIK3CA, are present 
in 25%–30% of human breast can-
cers, resulting in activation of the PI3 
kinase pathway (reviewed in Karakas 
et al., 2006). Armed with this knowl-
edge, Berns et al. showed that ecto-
pic expression of either wild-type or 
oncogenic mutant PIK3CA led to a 
trastuzumab resistance phenotype. 
Although mutant PIK3CA has been 
shown to be oncogenic, overexpres-
sion of wild-type PIK3CA is also onco-
genic, as amplification of this gene has 
been demonstrated in other malignan-
cies such as ovarian cancers. These 
results nicely complement findings 
from a study by Nagata et al. wherein 
loss of PTEN expression led to trastu-
zumab resistance (Nagata et al., 2004). 
Although Nagata et al. did not examine 
the effects of oncogenic PIK3CA, they 
demonstrated that PI3 kinase inhibi-
tors restored trastuzumab sensitivity 
in PTEN-deficient cells. Thus, Berns et 
al. have produced strong confirmatory 
evidence about the role of signaling 
via the PI3 kinase pathway in trastu-
zumab resistance.
A strength of both the current study 
and that of Nagata et al. is the attempt 
to validate preclinical findings in clini-
cal specimens. Berns et al. retrospec-
tively analyzed clinical outcome with 
respect to PTEN expression and 
PIK3CA mutations in a convenience 
sample of 55 primary HER2-over-
expressing breast cancers acquired 
from women who subsequently 
received trastuzumab-based therapy 
for advanced disease. Women whose 
tumors showed low PTEN expres-
sion showed a nonsignificant trend 
toward worse outcome compared with 
those whose tumors did not. Similarly, 
breast cancer patients with 
PIK3CA mutations in their 
tumors did not fare as well 
on trastuzumab therapy as 
those whose tumors had 
wild-type PIK3CA, but sta-
tistical significance was 
again not achieved. When 
these two groups were ana-
lyzed as one (activated PI3 
kinase pathway defined by 
low PTEN or mutant PIK3CA 
versus nonactivated PI3 
kinase pathway defined by 
high PTEN and wild-type 
PIK3CA), those women 
whose tumors showed an 
activated PI3 kinase path-
way did significantly worse 
than those whose tumors 
did not. This finding could 
argue that it is the activa-
tion of this pathway gener-
ally rather than alteration in a 
given gene per se that influ-
ences trastuzumab respon-
siveness. Of note, Nagata 
et al. did find a statisti-
cally significant correlation 
between low PTEN expres-
sion and relative resistance 
to trastuzumab therapy in 
another exploratory study. 
In their study, all 47 HER2-
overexpressing patients 
received trastuzumab with 
a taxane, whereas the current study 
included a heterogeneous group of 
HER2-overexpressing patients receiv-
ing trastuzumab with a number of dif-
ferent chemotherapy regimens. Thus, 
the confounding effects of different 
chemotherapeutic regimens and/or 
the small sample size studied could 
have potentially biased the results of 
the current study.
How can we interpret the results of 
Berns et al., and what do they mean 
for trastuzumab treatment of breast 
cancer? As with every in vitro and 
hypothesis-generating pilot study, 
one cannot apply these results to 
patient care at this time. However, 
given the increasing amount of data 
linking activation of the PI3 kinase 
pathway with trastuzumab resistance, 
it would be reasonable to examine 
the relationship between markers of 
figure 1. schematic of PI3 Kinase/AKT Pathway Regulation 
by PTen and PIK3cA
(A) Extracellular growth factor receptors (e.g., HER2) are receptor 
tyrosine kinases (RTK) that can phosphorylate and activate the PI3 
kinase/AKT pathway, resulting in a variety of cellular processes. The 
p110α catalytic subunit of PI3 kinase (PIK3CA) phosphorylates phos-
phatidylinositol 4, 5 bisphosphate (PIP2) to phosphatidylinositol 3, 4, 
5-triphosphate (PIP3). This reaction is inhibited by the tumor suppres-
sor PTEN. Ph, phosphorylation.
(B) In the absence of PTEN or the presence of mutant PIK3CA, cataly-
sis is driven from PIP2 to PIP3. This leads to activation of AKT1 and 
other molecules, resulting in cellular processes that favor neoplastic 
growth and transformation.298 Cancer Cell 12, October 2007 ©2007 Elsevier Inc.
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come with trastuzumab therapy in a 
larger group of HER2-overexpress-
ing breast cancer patients. If clini-
cally validated tests can be identified, 
such analyses might be carried out in 
samples collected from women with 
HER2-overexpressing breast cancer 
who participated in the four random-
ized clinical trials that established the 
value of trastuzumab in early breast 
cancer (Hudis, 2007; Romond et 
al., 2005; Smith et al., 2007). These 
studies have the virtue of large size, 
standardized chemotherapy, well-
annotated samples, and meticulous 
clinical follow-up, all crucial factors 
in the path to identifying a biomarker 
that will add value in clinical practice. 
In addition, these results suggest that 
combination therapies with PI3 kinase 
pathway inhibitors and trastuzumab 
may be more efficacious for some 
breast cancers with HER2 overex-
pression. Interestingly, a recent study 
of lapatinib, a small-molecule dual 
receptor tyrosine kinase inhibitor of 
the epidermal growth factor recep-
tor and HER2, showed that PTEN 
loss was not associated with lapitinib 
resistance (Xia et al., 2007). This may 
explain the clinical efficacy of lapatinib 
in trastuzumab-resistant patients and 
forms part of the rationale for a newly 
initiated global trial that will exam-
ine the impact of trastuzumab, lapa-
tinib, trastuzumab plus lapatinib, or a 
sequence of trastuzumab followed by 
lapatinib for women with early-stage 
HER2-overexpressing breast cancer.
Further, this study strongly sug-
gests that activation of the PI3 kinase 
pathway by any means may influence 
trastuzumab resistance. Therefore, it follows that reliable predictive biomark-
ers of response to trastuzumab therapy 
may encompass more than PTEN loss 
or PIK3CA mutation. For this reason 
Berns et al. also examined breast 
cancers for the AKT1 activating 
mutation recently reported by Carp-
ten et al. (2007) but did not identify 
this mutation in any of their patient 
samples. However, PI3 kinase sig-
naling ultimately leads to the activa-
tion of several downstream effectors, 
notably the mammalian target of 
rapamycin, or mTOR. Therefore, one 
can speculate that mTOR activation 
as measured by phosphorylation of 
downstream targets may also serve 
as useful predictive biomarkers for 
assessing response to trastuzumab 
therapy, a readily testable hypoth-
esis.
Lastly, while new biomarkers for 
trastuzumab response and resis-
tance such as PTEN expression and 
PIK3CA mutations are under evalu-
ation, it is important to recall that 
accurate measurement of HER2 is 
a vital step in the current manage-
ment of breast cancer patients, as its 
expression is the most powerful pre-
dictor of trastuzumab benefit at the 
present time. Multiple clinical stud-
ies have demonstrated that evalua-
tion of HER2 expression in routine 
clinical practice is far from perfect, 
and new guidelines to guide optimal 
HER2 evaluation have been issued 
by the American Society of Clinical 
Oncology and the College of Ameri-
can Pathologists (Wolff et al., 2007). 
Researchers across the whole of 
the translational continuum should 
always recall the imperative for 
appropriate development, validation, Cancer Cell 12and dissemination of a biomarker if it 
is to have an impact on human dis-
ease (Henry and Hayes, 2006).
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